对鼻腔 Staphylococcus aureus 脱殖的益生菌治疗的计算和体外评估
Burcu Tepekule1,2, Weronika Barcik1, Willy I Staiger1
1Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich 8091, Switzerland.
概括
益生菌治疗有效地消灭了像金黄色葡萄球菌 (Staphylococcus aureus) 这样的鼻腔病原体,为抗生素提供了强大的替代品. 这种方法增强了微生物群的多样性,并提供了个性化的选择,打击抗生素耐药性.
科学领域:
- 微生物学 微生物学
- 计算生物学 计算生物学
- 系统生物学 系统生物学
背景情况:
- 抗生素耐药性需要针对鼻腔病原体的新策略,例如金黄色葡萄球菌和肺炎性菌株菌.
- 目前的治疗依赖于抗菌药物,这些抗菌药物面临着日益增长的耐药性挑战.
- 共生细菌 (益生菌) 显示出抑制病原体的潜力.
研究的目的:
- 系统地研究益生菌治疗作为抗生素的替代品,用于消灭鼻腔病原生物.
- 开发和利用一个量化框架,结合数学建模和微生物群数据来模拟鼻子微生物组的动态.
- 为了比较益生菌与抗生素治疗的脱殖疗效和强度.
主要方法:
- 开发了一个定量框架,将数学建模与纵向16S rRNA amplicon测序数据集成在一起.
- 在S. aureus殖民患者中推断鼻腔微生物群体参数和模拟的微生物动态.
- 进行了体外实验,使用临床鼻子拭子来验证in silico发现.
主要成果:
- 与抗生素相比,益生菌治疗显示出优越的去殖民性能.
- 模拟显示,挑战后使用益生菌增强了重新殖民的稳定性.
- 在体外实验证实了抗生素治疗后S. aureus重新定居的益生菌抑制.
- 益生菌治疗导致微生物群多样性的附带减少较少.
结论:
- 益生菌疗法为抗生素提供了一个有希望的替代品,用于对抗鼻腔病原体和抗生素耐药性.
- 益生菌治疗在去殖民化,重新殖民化的强度和微生物群多样性保护方面具有优势.
- 可以使用患者特定的元基因组数据开发个性化治疗选择,从而增强治疗策略.
相关概念视频
Staphylococcal Skin Infections
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...


